Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxenda in ischemic cardiomyopathy
NCT02930265Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2016
- Primary completion
- Feb 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial of liraglutide in ischemic cardiomyopathy (ICM), sponsored by Chinese PLA General Hospital. Primary endpoint: Major Adverse Cardiovascular Events at 6 months. Status: unknown.
02
Drugs
03
Conditions
ischemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on NCT02930265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02930265.